Vertex Pharmaceuticals Non-GAAP EPS of $3.52 misses by $0.02, revenue of $2.1B beats by $30M
Vertex Pharmaceuticals press release  (NASDAQ:VRTX): Q1  Non-GAAP EPS of $3.52  misses by $0.02.
Revenue of $2.1B (+22.1% Y/Y)  beats by $30M.
Company reiterates full year 2022 product revenue guidance of $8.4 to $8.6 billion.